Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 5572 (miR-5572) is a human-specific, non-coding RNA molecule classified as a microRNA, which primarily functions through post-transcriptional regulation of gene expression by binding the 3′-UTR of target mRNAs. Increased expression of miR-5572 has been observed in the spinal cords of patients with sporadic amyotrophic lateral sclerosis (ALS) and is linked to decreased expression of SLC30A3, a zinc transporter gene implicated in cellular protection against ER and oxidative stress. Experimental evidence shows miR-5572 expression rises under low-zinc and ER stress conditions and its overexpression exacerbates cellular toxicity by promoting cell death associated with ER stress. The function of miR-5572 suggests a role in ALS pathogenesis and points to its potential as a biomarker, but there are no established therapeutic drugs targeting this microRNA and its utility as a direct therapeutic target remains unclear[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 5572 (miR-5572).